Madrigal Pharmaceuticals (MDGL) Long-Term Deferred Tax (2016 - 2023)

Madrigal Pharmaceuticals (MDGL) has reported Long-Term Deferred Tax for 8 consecutive years, with $383.2 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Long-Term Deferred Tax rose 41.36% year-over-year to $383.2 million; the TTM figure through Dec 2023 stood at $383.2 million (up 41.36% YoY), while the FY2023 annual figure was $383.2 million, up 41.36% from the prior year.
• Long-Term Deferred Tax climbed to $383.2 million in Q4 2023 per MDGL's latest filing, from $271.1 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $383.2 million in Q4 2023 and bottomed at $65.9 million in Q4 2019.
• Historically, Long-Term Deferred Tax has averaged $212.8 million across 5 years, with a median of $211.6 million in 2021.
• Annual changes were most pronounced in 2020 — Long-Term Deferred Tax surged 101.05% — and 2022, when it climbed 28.1%.
• Madrigal Pharmaceuticals' Long-Term Deferred Tax stood at $65.9 million in 2019, then soared by 101.05% to $132.4 million in 2020, then jumped by 59.85% to $211.6 million in 2021, then gained by 28.1% to $271.1 million in 2022, then jumped by 41.36% to $383.2 million in 2023.
• Business Quant data shows MDGL's Long-Term Deferred Tax at $383.2 million in Q4 2023, $271.1 million in Q4 2022, and $211.6 million in Q4 2021.